A new Phase 2 clinical trial evaluating difelikefalin was listed as recruiting on June 11, 2026. The study, titled "Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus," is registered under identifier NCT06593392.
The trial focuses on adolescent patients undergoing haemodialysis who experience moderate-to-severe pruritus. According to the registration, the study is in Phase 2 and is currently open for recruitment.
Difelikefalin is an approved compound, though this trial addresses a specific population and use case under investigation. The trial's primary focus, as stated in its title, is safety and tolerability rather than efficacy outcomes.
No results have been posted for this trial as of the listed date. The study status reflects active recruitment only, and no additional outcomes or findings are available at this time.
Readers interested in additional background on this compound can consult the compound overview for further context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT06593392"]